Fig. 7

CuB reversed EMT in Gefitinib resistant A549 cells via ROS and PI3K/Akt/mTOR pathway. a Western blotting assay was used to detect the EGFR, E-cadherin, N-cadherin and Vimentin expression in A549 and A549-GR cells after treatment with CuB (15 nM) or Gefitinib (10 μM) for 48 h. b The statistic results of a. ^###P < 0.001 vs A549 cells, ^*P < 0.05, ^***P < 0.001 vs A549-GR cells. c Western blotting assay was used to detect the p-PI3K, p-Akt and p-mTOR expression in A549 and A549-GR cells after treatment with CuB (15 nM) or Gefitinib (10 μM) for 48 h. d The statistic results of c. ^###P < 0.001 vs A549 cells, ^**P < 0.01, ^***P < 0.001 vs A549-GR cells. e The effect of CuB (15 nM) and Gefitinib (10 μM) on the ROS level in A549-GR cells for 48 h, and then treatment with DCFH₂DA (5 μM) for 30 min. f The quantification of Fig. 7e, ^###P < 0.001 vs A549 cells, ^***P < 0.001 vs A549-GR cells